Zahraa S. Qasim
Abstract
Background: The steady increase in microbial resistance is a global health problem as a result of uncontrolled use of antimicrobial drugs, In order to overcome the challenge, there is a continuous need to search for new antimicrobials by either investigate novel compounds or repurposing drugs i.e. identifying ...
Read More ...
Background: The steady increase in microbial resistance is a global health problem as a result of uncontrolled use of antimicrobial drugs, In order to overcome the challenge, there is a continuous need to search for new antimicrobials by either investigate novel compounds or repurposing drugs i.e. identifying new clinical use for existing approved agent thus saving time and cost required to develop a new antimicrobial therapy. Aim: This study aimed to assess the in vitro antimycotic activity of different concentrations of rosuvastatin against 4 different fungi isolated from patients with malignancies 1 mold of genus Aspergillus, of 3 spices (A. flavus, A.niger, and A. fumigatus) and 3 yeast of genus Candida of2species (C. albicans , and C. glabrata), one genus and species from each Saccharomyces cerevisiae , and Rhodotoryoa rubra by disc diffusion method. Materials and Methods: Sputum was taken from 30 patients with malignant disease, different micro and macroscopical tests were used to identified the 14 isolated fungi from them 1 genus from mold of Aspergillus, and 3 genus from yeast, from genus Aspergillus 3 species recognized as tailed, A. flavus, A. niger, and A.fumigatus. On the other handfrom yeast of genus Candida, C.albicans and C.glabrata, whereas from genus Saccharomyces, and Rhodotoula, Saccharomyces cerevisiae and Rhodotoula rubra were recognized. Results: Antimycotic susceptibility test exhibited zone of inhibition against yeast ranged from (30-20), (30-15), (30-15), and (25-15) against C.albicans, C.glabrata Saccharomyces cerevisiae and Rhodotoula rubra respectively, while mold show zone of inhibition ranged from (25-10), (10-0), and (30-10) against A.flavus, A.niger, and A.fumigatus respectively, although rosuvastatin show an antifungal activity only at dose 0.6 mg/ml against A. niger. Conclusion: Rosuvastatin has antifungal activity apart of its pleiotropic activity of statins.
Mais S. Saadallah; Omar A. Hamid
Abstract
Background: Transdermal drug delivery systems (TDDS) have been rapidly developed as a promising alternative to the oral delivery systems to provide controlled drug delivery and avoid the first-pass metabolism of drugs. Recently, various nanocarriers such as liposome and lipid nanoparticles have been ...
Read More ...
Background: Transdermal drug delivery systems (TDDS) have been rapidly developed as a promising alternative to the oral delivery systems to provide controlled drug delivery and avoid the first-pass metabolism of drugs. Recently, various nanocarriers such as liposome and lipid nanoparticles have been used to enhance dermal and transdermal penetration of drugs. The aim of this study is to formulate and evaluate a polymeric nanoparticle (PNPs)-loaded transdermal patch of the antihyperlipidemic drug rosuvastatin. Materials and Methods: Rosuvastatin PNPs were prepared by nanoprecipitation method, and evaluated for particle size, zeta-potential and polydispersity index. PNPs-loaded patch and PNPs-free patch (control) of rosuvastatin were prepared by solvent casting method using hydroxyl polymethyl cellulose K15 (HPMC K 15) as film-forming polymer and polyethylene glycol 200 (PEG 200) as a plasticizer and evaluated for physical appearance, thickness, folding endurance, surface pH, in-vitro release and ex-vivo permeability. Results: The particle size, zeta-potential, and polydispersity index of rosuvastatin-loaded PNPs were 68.69 nm, - 7.5 mV, and 0.294, respectively. The prepared transdermal films showed acceptable appearance, thickness, and folding endurance as well as surface pH values. In vitro release study showed 65% and 82% cumulative release after 24 hrs for the polymeric nanoparticle-loaded patch and control patch, respectively. However. ex vivo permeation results showed that a significantly higher amount of rosuvastatin permeated via rat skin from the PNPs-loaded patch in comparison to the control patch (P-value ˂ 0.05). Conclusion: Rosuvastatin PNPs-loaded transdermal patch was successfully prepared and revealed promising releasing and permeation properties comparing to control patch.